There are currently 5 ongoing clinical trials involving Cellulite
Of the 5 trials,2 trials are in Phase II
Furthermore, 2 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Cellulite, adermatology indication. North America and Europe are some of the prominent regionsengaged in Cellulite-related drug trials.
Cellulite related clinical trial sponsors
Cosmetic Laser Dermatology, L. Manetti H. Roberts & C SpA, and Endo International Plc are some of the notable clinical trial sponsors involved in Cellulite. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Cellulite
Metronidazole (Metronidazole) is the key marketed drug involving Cellulite.
Metronidazole (Metronidazole) is a synthetic imidazole derivative, acts as anti-bacterial and anti-infective agent. It functions via DNA Synthesis Inhibitor mechanism of action. It is formulated as tablets for oral route of administration. Metronidazole is marketed for the treatment of Cellulite and several other indications including Bacterial Pneumonia, Bacterial (Pyogenic) Meningitis, Abdominal Abscess, Cellulitis, Endometriosis, Emphysema, Endometrial Cancer, Acute Intestinal Amoebiasis, Amoebic Liver Abscess, Bacterial Endocarditis, Bacterial Sepsis, Folliculitis, Impetigo, Osteomyelitis, Pelvic Inflammatory Disease (Pelvic Infections), Prosthetic Joint infections, Spontaneous Bacterial Peritonitis, and Trichomonas Vaginitis. Metronidazole is marketed in China by Liaoning Aoda Pharmaceutical Co Ltd.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward